News & Events

In the news

Clean Mails – December 2022

Naobios signs a Research License Agreement with Valneva on EB66® cell line.

Naobios today announces the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation of alternative bioprocess design and new technologies.

Clean Mails – December 2022

Naobios, your partner in the production of Human Viral Challenge Agents

Naobios today announces its investment in the manufacturing of Human Viral Challenge Agents.

Clean Mails – September 2022

Naobios x GenSensor: a partnership for bioprocess optimization

Naobios and GenSensor, two renowned companies of the biopharma sector, have announced a partnership to further advance bioprocess optimization for clinical lots of viral vaccines and vectors. It will allow for enhanced bioprocesses and optimized scale-up.

Press Release

Naobios delivers FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the United States.

Clean Mails – May 2022

GMP biomanufacturing in a BSL-3 suite

A GMP biomanufacturing expert, Naobios has worked with numerous viruses requiring specific biocontainment procedures. Our state-of-the-art BSL-3 suite welcome hazardous microbes used for the generation of virus-based therapeutic products.

New webinar

How can customized solutions speed up successful GMP manufacturing?

The next edition of our webinar series will be centred on customised solutions when designing GMP processes to manufacture biologics and will take place on June, 23rd.

Discover our team:

Ysaline Roland, Production manager at Naobios

Our newest series of articles promote the people that make up our company and its human-centric values and objectives. Our latest profile is dedicated to Ysaline Roland, Production Manager at Naobios.

Collaboration

Naobios signs Service Agreement with Nobelpharma

Naobios will rely on its 15 years of expertise in process development and GMP manufacturing to support Nobelpharma develop its product. Naobios collaborated last year with the Japan-based company on preliminary studies.